OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

Tableside bong service? A Denver weed lounge aims to reinvent nightlife – The Cannabist

When Denverite Arend Richard looks at the local and national landscape for cannabis lounges, he sees a homogenous smattering of spaces designed for men. That’s

May 3, 2023

Galapagos, in makeover mode, strikes deal to make CAR-T therapies at blood centers across U.S.

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of

May 15, 2024

Bridging the gap in stroke care with virtual rehabilitation

A stroke often impacts a person’s ability to move their lower body from the hips down to the feet.

March 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.